Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune technologies. The news flow around MiNK centers on its progress in oncology, graft-versus-host disease (GvHD), transplantation, and severe pulmonary inflammatory disease, reflecting the company’s focus on immune reconstitution and immune modulation.
News updates commonly highlight clinical trial milestones for its lead iNKT therapy agenT-797, including Phase 1 and Phase 2 studies in checkpoint-refractory solid tumors, GvHD prevention in allogeneic stem cell transplantation, and critical pulmonary immune failure. MiNK also reports on preclinical and translational data for next-generation programs such as MiNK-215, an IL-15–enhanced, FAP-targeting CAR-iNKT therapy designed to remodel the tumor stroma and enhance anti-tumor immunity.
Investors following INKT news can expect coverage of peer-reviewed publications, late-breaking presentations at scientific meetings, grant awards from agencies such as NIH and the Department of Defense, and philanthropic funding supporting GvHD and transplant-related studies. Corporate news items also include quarterly financial results, at-the-market equity program updates, and leadership and board appointments that the company associates with advancing its iNKT platform toward pivotal development.
This news page aggregates MiNK Therapeutics’ press releases and related market-moving announcements in one place, making it easier to track clinical data readouts, regulatory and funding developments, and strategic initiatives involving its allogeneic iNKT cell therapy pipeline.
MiNK Therapeutics (NASDAQ: INKT) reported Q2 2024 results and provided a business update. Key highlights include:
- Expanded access to AgenT-797 in severe ARDS shows clinical efficacy
- Phase 2 study in 2L gastric cancer advancing with early data expected soon
- Phase 1 study in GvHD on track for activation in Q2 2024
- Successful PIPE financing raised $5.8 million at 25% premium
- Cash runway extended into 2025
- Q2 net loss of $2.7 million ($0.07 per share), down from $6.2 million ($0.18 per share) in Q2 2023
- Cash balance of $9.3 million as of June 30, 2024
MiNK is advancing its iNKT cell therapy programs, with promising results in ARDS and plans to fast-track IND filing for MiNK-215 CAR-iNKT therapy to early 2025.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has announced its plans to release second quarter 2024 financial results on August 13, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update. Interested parties can access the call via provided dial-in numbers or join the live webcast through the company's investor relations website.
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, has regained compliance with the Nasdaq Capital Market's market value of listed securities (MVLS) requirement. The company received confirmation from NASDAQ on July 23, 2024, that it has satisfied the MVLS requirement as outlined in Nasdaq Listing Rule 5550(b)(2). This development ensures MiNK Therapeutics' continued listing on the NASDAQ Capital Market, and the matter is now considered closed.
MiNK Therapeutics (NASDAQ: INKT) will hold its Annual Shareholders Meeting virtually on June 12, 2024, starting at 9:30 a.m. ET. Shareholders can register from 9:15 a.m. ET by visiting www.virtualshareholdermeeting.com/INKT2024 and using their 16-digit control number from proxy materials. Guests can access the meeting in listen-only mode without a control number. A live webcast and replay will be available on the company's website.
MiNK Therapeutics has unveiled clinical data on their allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, in a severe ARDS case at the ATS Annual Meeting. The subject, a 26-year-old post-renal transplant immunocompromised individual who developed severe hypoxemic respiratory failure due to COVID-19, was treated with a single dose of agenT-797. Significant clinical improvements included reduced inflammatory cytokines and successful extubation by day 37. The patient was discharged by day 60 and resumed normal activities within six months. These findings align with Phase 1 trial data, supporting the potential of agenT-797 in treating severe respiratory conditions in immune-compromised patients.
MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2024 results, highlighting significant progress in its invariant natural killer T (iNKT) cell therapy programs. Key developments include a $5.8 million private placement financing at a 25% premium, which will expedite the clinical entry of MiNK-215 for solid tumors. Clinical trials for agenT-797 in gastroesophageal cancers are ongoing, with initial results expected later in 2024. Preclinical data showcased MiNK-215's potential in treating MSS colorectal cancer liver metastases. Financially, MiNK ended the quarter with $5.8 million in cash, reduced net losses to $3.8 million (down from $5.7 million in Q1 2023), and decreased operating expenses.
MiNK Therapeutics, Inc. announced a $5.8 million private placement financing to advance the clinical trials of MiNK-215, their leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein in solid tumors. The financing includes a 25% premium, selling 4,640,000 shares of common stock at $1.25 per share. The funding will help accelerate the clinical development of MiNK-215, planned to enter the clinic in early 2025. Additionally, Katie Chudnovsky has been appointed as a Board Observer, bringing extensive experience in the medical research field.
MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its first quarter 2024 financial results on May 14, 2024. The company is focused on developing iNKT cell therapies for cancer and immune diseases. An executive conference call and webcast will follow to discuss the results and provide a corporate update.
FAQ
What is the current stock price of Mink Therapeutics (INKT)?
What is the market cap of Mink Therapeutics (INKT)?
